0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Contribution |

Phenotypic Variability Among Adult Siblings With Sjögren-Larsson Syndrome FREE

Alexander Lossos, MD; Moona Khoury, MD; William B. Rizzo, MD; John M. Gomori, MD; Eyal Banin, MD, PhD; Abraham Zlotogorski, MD; Saleh Jaber, MD; Oded Abramsky, MD, PhD; Zohar Argov, MD; Hanna Rosenmann, PhD
[+] Author Affiliations

Author Affiliations: Department of Neurology, Agnes Ginges Center for Human Neurogenetics (Drs Lossos, Abramsky, Argov, and Rosenmann), and Departments of Radiology (Dr Gomori), Ophthalmology (Dr Banin), Dermatology (Dr Zlotogorski), and Orthopedics (Dr Jaber), Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Internal Medicine, Carmel Medical Center, Haifa, Israel (Dr Khoury); and Department of Pediatrics, University of Nebraska Medical Center, Omaha (Dr Rizzo).


Arch Neurol. 2006;63(2):278-280. doi:10.1001/archneur.63.2.278.
Text Size: A A A
Published online

Background  Sjögren-Larsson syndrome (SLS) is an early childhood–onset disorder with ichthyosis, mental retardation, spastic paraparesis, macular dystrophy, and leukoencephalopathy caused by the deficiency of fatty aldehyde dehydrogenase due to mutations in the ALDH3A2 gene (the gene that encodes microsomal fatty aldehyde dehydrogenase). Cerebral proton magnetic resonance spectroscopy in those with SLS demonstrates an abnormal white matter peak at 1.3 ppm, consistent with long-chain fatty alcohol accumulation.

Objective  To define the clinical course and proton magnetic resonance spectroscopic findings of SLS in adults.

Design and Setting  Case series in a tertiary care center.

Patients  Six siblings of a consanguineous Arab family with early childhood–onset SLS who carry the 682C→T mutation in the ALDH3A2 gene were reinvestigated in adulthood.

Results  The 6 affected siblings ranged in age from 16 to 36 years. All exhibited the typical clinical and imaging manifestations of SLS, but their severity markedly varied. Neurological involvement was apparently nonprogressive, and its severity showed no correlation with age. Cerebral proton magnetic resonance spectroscopy showed a lipid peak at 1.3 ppm, with decreasing intensity in the older siblings.

Conclusion  These observations document significant clinical variability and the nonprogressive neurological course of SLS in adult siblings with the same ALDH3A2 genotype, and demonstrate possible correlation of proton magnetic resonance spectroscopic changes with age, suggesting unknown pathogenic mechanisms to compensate for the responsible biochemical defect in this disease.

Sjögren-Larsson syndrome (SLS) (Online Mendelian Inheritance in Man 270200) is an autosomal recessive disorder characterized by congenital ichthyosis, mental retardation, spastic paraparesis, and leukoencephalopathy.1 Additional manifestations include perimacular glistening white dots, photophobia, seizures, and the development of leg contractures. The neurological features of SLS appear in the first few years of life and then seem to stabilize.2 Most described patients have been children,2,3 and less is known about the long-term clinical course in adults.

Sjögren-Larsson syndrome is caused by mutations in the ALDH3A2 gene, which encodes microsomal fatty aldehyde dehydrogenase.1 Fatty aldehyde dehydrogenase deficiency results in impaired oxidation of long-chain fatty aldehydes to fatty acids. The consequent accumulation of fatty aldehyde precursors, including fatty alcohols, or the formation of aldehyde-modified macromolecules is postulated to affect the normal formation of multilamellar membranes in the stratum corneum and myelin, and to result in the symptoms.4 Cerebral proton magnetic resonance spectroscopy (1H-MRS) in those with SLS demonstrates an abnormal white matter peak, consistent with long-chain fatty alcohol accumulation, that emerges in infancy and coincides with retarded myelination.3 Although the severity of the neurological deficit may vary among SLS patients, little is known about genotype-phenotype correlations in this disease.

To further define the clinical course of SLS in adults and to determine the phenotypic variation among siblings, we investigated a large multiplex SLS family.

Early clinical and computed tomographic imaging results in 6 affected siblings of a consanguineous Arab SLS family were previously published.5 The diagnosis was subsequently confirmed by finding reduced fibroblast fatty aldehyde dehydrogenase activity (4% of normal) in the proband and genetic linkage to chromosome 17p11.26 with identification of the 682C→T missense mutation in the ALDH3A2 gene.7 Homozygosity for 682C→T has been reconfirmed in all 6 patients using polymerase chain reaction amplification of exon 5 with the reported primers and digestion by the restriction enzyme NsiI.7

Patients were reexamined using clinical and functional scoring, as published.2 Informed consent from the patients or the legal guardian was obtained. Performance on standard intelligence tests was integrated with school and communication skills for the estimation of mental retardation, defined as mild for an IQ of 55 to 69 and borderline for an IQ of 70 to 79.2 The ocular examination included measurement of best-corrected Snellen visual acuity, refraction, slitlamp biomicroscopy, and indirect ophthalmoscopy. Color vision was assessed using the Ishihara 38-plate test and the Farnsworth D-15 dichotomous test. Three patients were also examined with full-field electroretinography according to the International Society for Clinical Electrophysiology of Vision standards using corneal Burian-Allen electrodes and a computerized system (UTAS 3000; LKC Technologies, Gaithersburg, Md); rod, cone, and element cone-rod responses were recorded. Peripheral nerve conduction study of the peroneal and sural nerves was performed in 5 patients. Cerebral magnetic resonance imaging was done on a 1.5-T unit; axial and sagittal images were obtained with T1-weighted, T2-weighted, and fluid-attenuated inversion recovery sequences. The 1H-MRS was performed on a 3.4-mL volume of interest placed in the periventricular white matter with the maximal signal abnormality and in the basal ganglia using the PRESS sequence with echo times of 36 and 135 milliseconds and a repetition time of 1500 milliseconds. Spectra were specifically evaluated for the narrow peak at 1.3 ppm,3 and relative peak intensity ratios of the metabolites were calculated.

The 6 affected siblings ranged in age from 16 to 36 years. All exhibited the major clinical features of SLS, but their severity varied (Table). Ichthyosis was generalized in distribution, and was most prominent over the trunk and extremities, but spared the head, palms, and soles. Although all patients exhibited spastic paraparesis, they differed in their ability to ambulate. Patients 1 and 2 also had mild hyperreflexia in the arms, and patients 2, 3, and 4 displayed an inappropriate emotional response, but none had seizures or signs of peripheral nerve involvement. The severity of cutaneous and neurological manifestations showed no apparent correlation with age. The number of macular glistening white dots tended to be higher in the older patients. This generally correlated with a decrease in visual acuity, suggesting progressive macular dysfunction. In contrast, the results of full-field electroretinography were normal, even in the oldest sibling, indicating that the extramacular retinal function remains preserved.

Table Graphic Jump LocationTable. Clinical and Laboratory Findings in the 6 Siblings With Sjögren-Larsson Syndrome Due to the 682C→T ALDH3A2 Gene Mutation*

Consistent with the clinical findings, all 4 siblings studied by MR imaging had symmetric cerebral white matter abnormalities, but their extent, distribution, and pattern varied (Table). Patchy T2-weighted and fluid-attenuated inversion recovery signal hyperintensities were observed in patient 3, whereas confluent lesions were present in patients 1, 4, and 6 and tended to correlate with their functional disability. Subcortical U fibers, cerebral gray matter, ventricular size, and the cerebellum seemed unaffected. The most significant 1H-MRS finding was the presence of a prominent sharp lipid peak at 1.3 ppm in the affected cerebral white matter, with a decreasing lipid-creatine ratio in the older siblings (Table). This peak was visible at a short echo time in all the studies, but not at a long echo time in the 2 oldest siblings. A smaller peak at 0.9 ppm3 was also seen, and basal ganglia spectra were normal. Other metabolites seen on 1H-MRS did not correlate with age.

Comparison of the current clinical status with the more qualitative data 11 years earlier5 showed a similar distribution of the neurological deficit in individual patients and no apparent deterioration. All subjects reside in one village and consume a diet customary to their community.

To our knowledge, this is the largest described family with genetically confirmed SLS, and it provides a unique opportunity to define the intrafamilial clinical variation, particularly in adults. A previous study5 of this family in 1987, before the genetic defect in SLS was discovered, had a paucity of clinical information and used older imaging techniques. Therefore, longitudinal comparisons of the natural history of SLS in this family are limited. Several conclusions, however, may be drawn from these studies.

First, the neurological involvement in our adult SLS patients, based on physical examination, is apparently nonprogressive, and its severity does not correlate with age. Although slow progression remains a possibility, prior observations in children with SLS tend to support this conclusion.2,3 In this aspect, SLS could superficially resemble forms of cerebral palsy or other static encephalopathies of childhood.8 Obviously, most of the clinical and MR imaging disease burden in those with SLS is attained early in life. This may be the result of selective vulnerability of the brain to lipid abnormalities during myelin maturation.9

Second, phenotypic variation, even among siblings, may be significant. Despite identical ALDH3A2 genotypes and apparently similar environmental exposures and diets, the affected siblings differed in the severity of cutaneous disease, neurological impairment, and brain imaging results. Most mutations in SLS are private,10 and there are few studies comparing the clinical disease among patients with the same ALDH3A2 genotype, either within or across kindreds. The clinical variation seen in our family suggests that additional unknown genetic or environmental factors exist to compensate for the responsible biochemical defect.2 Furthermore, distinct pathogenic mechanisms may act in different tissues to account for the discordance between cutaneous and neurological involvement and for the progressive macular dystrophy.1

Third, the intensity of the cerebral 1H-MRS white matter lipid peak at 1.3 ppm was inversely correlated with the age of the siblings. Although this signal may fluctuate in intensity11 and we have no serial 1H-MRS data on individual patients or statistical confirmation, the decrease in the 1.3-ppm peak among older siblings was striking. Moreover, review of the published cerebral 1H-MRS data in a large series of SLS patients reveals a similar trend that was not previously noted.3 Because this peak is highly characteristic of SLS and probably represents accumulation of fatty alcohols or their metabolites beginning in infancy,3 it is tempting to speculate that its decline in adults reflects decreasing levels of the same lipids, indicating reduced activity of the disease. That the peak was not seen at a long echo time in the 2 oldest siblings is probably due to its low intensity. It is unlikely that the decrease in the lipid peak reflects progressive loss of myelin, because there was no apparent worsening of the MR imaging findings in the older siblings or of neurological symptoms with age.

The new observations in our SLS family suggest that the clinical course in some adults may reveal previously unknown pathogenic mechanisms of this disease.

Correspondence: Alexander Lossos, MD, Department of Neurology, Hadassah University Hospital, PO Box 12000, Jerusalem 91120, Israel (alos@hadassah.org.il).

Accepted for Publication: June 16, 2005.

Author Contributions:Study concept and design: Lossos, Khoury, Rizzo, and Rosenmann. Acquisition of data: Lossos, Khoury, Rizzo, Gomori, Banin, Zlotogorski, Jaber, Argov, and Rosenmann. Analysis and interpretation of data: Lossos, Khoury, Rizzo, Gomori, Banin, Zlotogorski, Abramsky, Argov, and Rosenmann. Drafting of the manuscript: Lossos, Rizzo, and Rosenmann. Critical revision of the manuscript for important intellectual content: Lossos, Khoury, Rizzo, Gomori, Banin, Zlotogorski, Jaber, Abramsky, Argov, and Rosenmann. Obtained funding: Lossos, Banin, and Abramsky. Administrative, technical, and material support: Lossos, Khoury, and Abramsky. Study supervision: Lossos, Gomori, Zlotogorski, Abramsky, Argov, and Rosenmann.

Funding/Support: This study was supported in part by the Hadassah International France Fund for Hereditary Spastic Paraplegia, Paris; a Yedidut research grant from Friends of the Hebrew University (Mexican Chapter), Mexico City, Mexico; and the Authority for Research and Development, Hebrew University of Jerusalem, Jerusalem.

Previous Presentation: This study was presented as part of the doctoral thesis of Dr Khoury at Hadassah-Hebrew University Medical School; March 1, 2002; Jerusalem.

Acknowledgment: We thank the patients and their family for participation in the study.

Rizzo  WB Sjögren-Larsson syndrome: fatty aldehyde dehydrogenase deficiency.  In: Scriver  CR, Beaudet  AL, Sly  WS, Valle  D, eds. The Metabolic and Molecular Bases of Inherited Disease.8th ed. New York, NY: McGraw-Hill Co; 2001:2239-2258
Willemsen  MAIjlst  LSteijlen  PM  et al.  Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome. Brain 2001;124(pt 7)1426- 1437
Link to Article
Willemsen  MAvan der Graaf  Mvan der Knaap  MS  et al.  MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004;25649- 657
PubMed
Rizzo  WB Sjögren-Larsson syndrome. Neurology 1999;521307- 1308
PubMed Link to Article
Gomori  JMLeibovici  VZlotogorski  AWirguin  IHaham-Zadeh  S Computed tomography in Sjögren-Larsson syndrome. Neuroradiology 1987;29557- 559
PubMed Link to Article
Rogers  GRRizzo  WBZlotogorski  A  et al.  Genetic homogeneity in Sjögren-Larsson syndrome. Am J Hum Genet 1995;571123- 1129
PubMed
Rizzo  WBCarney  GLin  Z The molecular basis of Sjögren-Larsson syndrome. Am J Hum Genet 1999;651547- 1560
PubMed Link to Article
Lyon  GAdams  RDKolodny  EH Neurology of Hereditary Metabolic Diseases of Children. 2nd ed. New York, NY: McGraw-Hill Co; 1996
van der Knaap  MSValk  J Magnetic Resonance of Myelin, Myelination, and Myelin Disorders. 2nded. Berlin, Germany: Springer-Verlag; 1995
Carney  GWei  SRizzo  WB Sjögren-Larsson syndrome: seven novel mutations in the fatty aldehyde dehydrogenase gene ALDH3A2. Hum Mutat 2004;24186
PubMed Link to Article
Willemsen  MALutt  MASteijlen  PM  et al.  Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome. Eur J Pediatr 2001;160711- 717
PubMed Link to Article

Figures

Tables

Table Graphic Jump LocationTable. Clinical and Laboratory Findings in the 6 Siblings With Sjögren-Larsson Syndrome Due to the 682C→T ALDH3A2 Gene Mutation*

References

Rizzo  WB Sjögren-Larsson syndrome: fatty aldehyde dehydrogenase deficiency.  In: Scriver  CR, Beaudet  AL, Sly  WS, Valle  D, eds. The Metabolic and Molecular Bases of Inherited Disease.8th ed. New York, NY: McGraw-Hill Co; 2001:2239-2258
Willemsen  MAIjlst  LSteijlen  PM  et al.  Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome. Brain 2001;124(pt 7)1426- 1437
Link to Article
Willemsen  MAvan der Graaf  Mvan der Knaap  MS  et al.  MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004;25649- 657
PubMed
Rizzo  WB Sjögren-Larsson syndrome. Neurology 1999;521307- 1308
PubMed Link to Article
Gomori  JMLeibovici  VZlotogorski  AWirguin  IHaham-Zadeh  S Computed tomography in Sjögren-Larsson syndrome. Neuroradiology 1987;29557- 559
PubMed Link to Article
Rogers  GRRizzo  WBZlotogorski  A  et al.  Genetic homogeneity in Sjögren-Larsson syndrome. Am J Hum Genet 1995;571123- 1129
PubMed
Rizzo  WBCarney  GLin  Z The molecular basis of Sjögren-Larsson syndrome. Am J Hum Genet 1999;651547- 1560
PubMed Link to Article
Lyon  GAdams  RDKolodny  EH Neurology of Hereditary Metabolic Diseases of Children. 2nd ed. New York, NY: McGraw-Hill Co; 1996
van der Knaap  MSValk  J Magnetic Resonance of Myelin, Myelination, and Myelin Disorders. 2nded. Berlin, Germany: Springer-Verlag; 1995
Carney  GWei  SRizzo  WB Sjögren-Larsson syndrome: seven novel mutations in the fatty aldehyde dehydrogenase gene ALDH3A2. Hum Mutat 2004;24186
PubMed Link to Article
Willemsen  MALutt  MASteijlen  PM  et al.  Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome. Eur J Pediatr 2001;160711- 717
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 11

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Collections
PubMed Articles